Cavion, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cavionpharma.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Cavion, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02202993
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Cavion, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01550458
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
News
No news found